106 results
Page 2 of 6
ARS
1wpim1 8gsyghdbnrpa
1 May 23
Annual report to shareholders
1:52pm
424B5
s5cqjbbcflbh k7wfag
14 Sep 22
Prospectus supplement for primary offering
4:12pm
424B5
qymyd9b79a0d uc9p
13 Sep 22
Prospectus supplement for primary offering
5:19pm
8-K
EX-99.2
2j6wmwk
12 Sep 22
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
7:54am
8-K
EX-99.1
6j3 z10az4f8
12 Sep 22
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
7:54am
424B3
dqgyag7atu
11 Jul 22
Prospectus supplement
4:32pm
POS AM
qa4r4 iqp89pmv
1 Jul 22
Prospectus update (post-effective amendment)
4:17pm
S-3
EX-4.7
2bzpdco2zlgycn rcc
1 Jul 22
Shelf registration
4:13pm
S-3
ejk81ij5npng9xe
1 Jul 22
Shelf registration
4:13pm
S-3
EX-1.2
vo3vy9sjv0m4k9sm2s7
1 Jul 22
Shelf registration
4:13pm
S-3
EX-4.6
ju8jdiw6gzz3kyr4g7a
1 Jul 22
Shelf registration
4:13pm
424B3
o7phue1vmm30
13 May 22
Prospectus supplement
8:18am
DEF 14A
d03gf
28 Apr 22
Definitive proxy
8:36am